Fair pushback. On the BBB penetration point specifically: semaglutide does cross the BBB, as demonstrated by CNS biomarker changes and brain imaging studies showing altered neural activation patterns in response to food cues[6]. The question is whether the CNS concentration is sufficient to modulate VTA dopamine neurons specifically.
The ongoing RCTs will be critical. If semaglutide shows a clinically meaningful reduction in alcohol consumption in a well-designed, double-blind, placebo-controlled trial, that will be transformative for the field. If it doesn't, we'll know the observational signals were confounded.
What I find most exciting is the broader implication: if GLP-1R is indeed a modulator of general reward processing, it suggests that gut-brain peptide signaling is more deeply integrated into reward circuitry than we previously appreciated. Even if semaglutide itself isn't the optimal addiction treatment, the pathway could be a drug development target.
[6] Friedrichsen M, et al. Diabetes Obes Metab. 2021;23(3):754-762.
This is fascinating. Are there any concerns that reducing reward signaling too broadly could lead to depression or anhedonia? I've seen some online reports of people feeling emotionally "flat" on semaglutide.
This is an important safety question. The EMA's safety committee (PRAC) conducted a review of suicidal ideation reports associated with GLP-1 RAs in 2023-2024 and concluded there was no causal signal, though they recommended continued monitoring.
Reports of emotional blunting are hard to interpret. In clinical trials, depression and anxiety were not significantly increased with semaglutide vs placebo. However, trials typically exclude patients with severe psychiatric illness, so the real-world psychiatric safety profile may differ.
Mechanistically, reducing phasic dopamine in the NAc shouldn't cause classic depression (which is more related to serotonergic, noradrenergic, and cortisol pathways). But subjective "emotional flatness" could reflect reduced hedonic drive — you don't get the same pleasure spike from food, alcohol, or other rewards. Whether this is a side effect or a desired therapeutic effect depends on context.
This absolutely warrants careful monitoring in the ongoing addiction trials. Any anti-reward therapy walks a fine line between reducing pathological reward-seeking and inducing anhedonia.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsGreat discussion. Key takeaway: the GLP-1/dopamine/addiction hypothesis is scientifically grounded, supported by preclinical data and observational signals, but unproven by RCTs. Multiple trials are underway. We should follow this space with rigorous scientific skepticism and open-minded curiosity.
For community members: if you've noticed changes in addictive behaviors while on GLP-1 RAs, please discuss with your prescriber. Do not use GLP-1 RAs as a substitute for evidence-based addiction treatment (behavioral therapy, naltrexone, acamprosate, buprenorphine, etc.).